Abstract
In this section, a novel approach for identifying MDM2-p53 and MDMX-p53 protein–protein interactions (PPIs) inhibitors by using chemically synthesized MDM2 and MDMX proteins has been established. MDM2 and MDMX are oncoproteins that negatively regulate the activity and stability of the tumor suppressor protein p53. The inhibitors of PPIs of MDM2-p53 and MDMX-p53 represent potential anticancer agents. Affinity-based chemical array screening is one of the efficient methods for identification of binding agents toward various pockets of proteins. To establish chemistry-based screening platform for identification of MDM2 and MDMX inhibitors, synthetic strategy of MDM2 and MDMX proteins and application of these proteins for chemical array screening were performed. MDM2 and MDMX proteins were prepared by Fmoc-based solid-phase peptide synthesis (SPPS), and binding candidates for them were identified from an in-house compound library by chemical array screening. The subsequent fluorescence polarization (FP) assay identified peptidic compounds that inhibited MDM2-p53 and MDMX-p53 interactions.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
(a) Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6:909–923; (b) Wade M, Wang YV, Wahl GM (2010) The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 20:299–309
(a) Cahilly-Snyder L, Yang-Feng T, Francke U, George DLS (1987) Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Cell Mol Genet 13:235–244; (b) Momand J, Zambetti GP, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237–1245; (c) Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362:857–860l; (d) Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M, van Ham RC, van der Houven van OW, Hateboer G, van der Eb AJ, Jochemsen AG (1996) MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J, 15:5349–5357
Honda R, Tanaka H, Yasuda H (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 22:25–27; (b) Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296–299; (c) Micheal D, Oren M (2003) The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 13:49–58; (d) Stommel JM, Wahl GM (2005) A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle 4:411–417
Sharp DA, Kratowicz SA, Sank MJ, George DL (1999) Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J Biol Chem 274:38189–38196; (b) Marine JCW, Dyer MA, Jochemsen AG (2007) MDMX: from bench to bedside. J Cell Sci 120:371–378; (c) Wang X (2011) p53 regulation: teamwork between RING domains of Mdm2 and MdmX. Cell Cycle 10:4225–4229; (d) Wang X, Wang J, Jiang X (2011) MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. J Biol Chem 286:23725–23734
Wade M, Li YC, Wahl GM (2013) MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 13:83–96
Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844–848
Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, Zhu F, Mills N, Smithson DC, Regni CA, Bashford D, Cicero SA, Schulman BA, Jochemsen AG, Guy RK, Dyer MA (2010) Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem 285:10786–10796
Pazgier M, Liu M, Zou G, Yuan W, Li C, Li C, Li J, Monbo J, Zella D, Tarasov SG, Lu W (2009) Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci U S A 106:4665–4670
Liu M, Pazgier M, Li C, Yuan W, Li C, Lu W (2010) A left-handed solution to peptide inhibition of the p53-MDM2 interaction. Angew Chem Int Ed 49:3649–3652
Tsuganezawa K, Nakagawa Y, Kato M, Taruya S, Takahashi F, Endoh M, Utata R, Mori M, Ogawa N, Honma T, Yokoyama S, Hashizume Y, Aoki M, Kasai T, Kigawa T, Kojima H, Okabe T, Nagano T, Tanaka A (2013) A fluorescent-based high-throughput screening assay for small molecules that inhibit the interaction of MdmX with p53. J Biomol Screen 18:191–198
Czarna A, Popowicz GM, Pecak A, Wolf S, Dubin G, Holak TA (2009) High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx. Cell Cycle 8:1176–1184
Joseph TL, Madhumalar A, Brown CJ, Lane DP, Verma CS (2010) Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies. Cell Cycle 9:1167–1181
Hu B, Gilkes DM, Faroogi B, Sebti SM, Chen J (2006) MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 281:33030–33035
Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R, Graaf P, Francoz S, Gasparini P, Gobbi A, Helin K, Pelicci PG, Jochemsen AG, Marine JC (2004) Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol Cell Biol 24:5835–5843
Kondoh Y, Honda K, Osada H (2015) Construction and application of a photo-cross-linked chemical array. Methods Mol Biol 1263:29–41
Noguchi T, Oishi S, Honda K, Kondoh Y, Saito T, Kubo T, Kaneda M, Ohno H, Osada H, Fujii N (2013) Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors. Bioorg Med Chem Lett 23:3802–3805
Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80–83
Lin DL, Chang C (1996) p53 is a mediator for radiation-repressed human TR2 orphan receptor expression in MCF-7 cells, a new pathway from tumor suppressor to member of the steroid receptor superfamily. J Biol Chem 271:14649–14652
(a) Wang P, Dong S, Shieh JH, Peguero E, Hendrickson R, Moore MA, Danishefsky SJ (2013) Erythropoietin derived by chemical synthesis. Science 342:1357–1760; (b) Seenaiah M, Jbara M, Mali SM, Brik A (2015) Convergent versus sequential protein synthesis: the case of ubiquitinated and glycosylated H2B. Angew Chem Int Ed 54:12374–12378
Kent SBH, Milton SCF, Milton RCD (1993) D-enzyme compositions and methods of their use. Patent WO 9325667
Sankaranarayanan S, Sharma A, Chattopadhyay S (2002) Synthesis of the 1,5-dimethylic chiron enantiomers, 3,7,11-trimethyldodec-10-en-1-ol: application to enantiomeric syntheses of tribolure and a marine fatty acid. Tetrahedron Asymmetry 13:1373–1378
Cohen N, Scott CG, Neukom C, Lopresti RJ, Weber G, Saucy G (1981) Total Synthesis of All Eight Stereoisomers of α-Tocopheryl Acetate. Determination of their diastereoisomeric and enantiomeric purity by gas chromatography. Helv Chim Acta 64:1158–1173
Muller T, Coowar D, Hanbali M, Heushling P, Luu B (2006) Improved synthesis of tocopherol fatty alcohols and analogs: microglial activation modulators. Tetrahedron 62:12025–12040
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Noguchi, T. (2018). Development of a Mirror-Image Screening System for Chiral Natural Products. In: Development of Chemistry-Based Screening Platform for Access to Mirror-Image Library of Natural Products. Springer Theses. Springer, Singapore. https://doi.org/10.1007/978-981-10-6623-8_2
Download citation
DOI: https://doi.org/10.1007/978-981-10-6623-8_2
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-6622-1
Online ISBN: 978-981-10-6623-8
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)